ArticleThe Journal of clinical investigation2023
Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation.
Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Effect of Combined Renal Denervation and Pulmonary Vein Isolation on Atrial Fibrillation: A Systematic Meta-Analysis.Anatolian journal of cardiology · 2025Pooled it
- The preventive effect of sodium-glucose co-transporter-2 inhibitors on atrial fibrillation and atrial flutter in patients with chronic kidney disease: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Estimated Plasma Volume Status May Modify the Association between Estimated Glomerular Filtration Rate and Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: A post hoc Analysis of the TOPCAT Trial.Cardiorenal medicine · 2026Trial
- Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Trial
- NIMA-Related Kinase-7 Activates Atrial Cardiomyocyte NLRP3 Inflammasome and Associates With Occurrence of Postoperative Atrial Fibrillation.Circulation. Arrhythmia and electrophysiology · 2026Article
- Utility of Risk Scores for Predicting Stroke and Intracranial Bleeding Across Levels of Kidney Function in Two Large Community-Based Cohorts of Older Adults With Atrial Fibrillation.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Article
- Molecular Synergy and Inflammatory Activation in Pathogenesis and Therapy of Atrial Cardio-Metabolic Cardiomyopathy.JACC. Basic to translational science · 2026Article
- The Immune System as a Proarrhythmic Mediator: A Novel Paradigm for the Development of New Antiarrhythmic Therapy.The Canadian journal of cardiology · 2026Review
- The clinical pathophysiology of atrial fibrillation: outstanding questions from bedside to bench and back.Physiological reviews · 2026Review
- Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes: A Prospective Clinical and Cardiometabolic Analysis.Life (Basel, Switzerland) · 2026Article
- Elevated red cell distribution width as a prognostic indicator in critically ill patients with atrial fibrillation and chronic kidney disease.BMC cardiovascular disorders · 2026Article
- P2X7 receptors promote atrial remodeling and atrial fibrillation susceptibility via reactive oxygen species-mediated mitogen-activated protein kinase signaling activation.Journal of cell communication and signaling · 2026Article
- Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment.Nature reviews. Cardiology · 2026Review
- Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation.European heart journal · 2026Article
- Systematic Review and Meta-Analysis of the Frequency of Thromboembolic Events, Bleeding, and Mortality in Patients with Atrial Fibrillation and End-Stage Renal Disease Undergoing Percutaneous Left Atrial Appendage Closure.Journal of clinical medicine · 2026Review
- Development and validation of a nomogram model based on inflammatory markers and cardiac parameters: predicting the risk of recurrence in patients with atrial fibrillation after radiofrequency catheter ablation.BMC cardiovascular disorders · 2026Article
- Gut microbiota dysbiosis promotes chronic kidney disease-associated atrial fibrillation through activation of the NLRP3 inflammasome.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Cellular and molecular cross-talk in atrial fibrillation: The role of non-cardiomyocytes in creating an arrhythmogenic substrate.The Journal of physiology · 2026Review
- Efficacy of rhBNP in heart failure with atrial fibrillation combined with poor conventional therapy response and recurrence risk factors.American journal of translational research · 2026Article
- NLRP3 inflammasome in cardiovascular diseases: molecular mechanisms and advances in targeted drug research.Frontiers in immunology · 2026Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 7 countries.
Funding
Abstract
Chronic kidney disease (CKD) is associated with a higher risk of atrial fibrillation (AF). The mechanistic link between CKD and AF remains elusive. IL-1β, a main effector of NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation, is a key modulator of conditions associated with inflammation, such as AF and CKD. Circulating IL-1β levels were elevated in patients with CKD who had AF (versus patients with CKD in sinus rhythm). Moreover, NLRP3 activity was enhanced in atria of patients with CKD. To elucidate the role of NLRP3/IL-1β signaling in the pathogenesis of CKD-induced AF, Nlrp3-/- and WT mice were subjected to a 2-stage subtotal nephrectomy protocol to induce CKD. Four weeks after surgery, IL-1β levels in serum and atrial tissue were increased in WT CKD (WT-CKD) mice versus sham-operated WT (WT-sham) mice. The increased susceptibility to pacing-induced AF and the longer AF duration in WT-CKD mice were associated with an abbreviated atrial effective refractory period, enlarged atria, and atrial fibrosis. Genetic inhibition of NLRP3 in Nlrp3-/- mice or neutralizing anti-IL-1β antibodies effectively reduced IL-1β levels, normalized left atrial dimensions, and reduced fibrosis and the incidence of AF. These data suggest that CKD creates a substrate for AF development by activating the NLRP3 inflammasome in atria, which is associated with structural and electrical remodeling. Neutralizing IL-1β antibodies may be beneficial in preventing CKD-induced AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.